Natera CFO sells more than $219,000 in company stock Author: Investing.com



Natera, Inc. (NASDAQ: ) Chief Financial Officer Michael Burkes has sold stock in the company, according to a recent SEC filing. The transactions took place over three days and totaled more than $219,000 in sales.

The price range for the sale was $89.55 to $92.9991 per share. On April 24, Burkes sold 937 shares at a price of approximately $92.9991 per share. The next day, an additional 705 shares were sold at $89.55 per share. Trading continued on April 26, with the sale of 751 shares at $92 per share.

Following those transactions, filings showed Burks still owned a significant stake in the company. Investors often monitor insider sales because they can get insight into what senior executives think of a company's current valuation and future prospects.

The sales reported were executed in accordance with Burkes' Rule 10b5-1 trading plan adopted on March 14, 2023. Provides defense against insider trading charges.

These recent sales by Natera executives are likely to attract the attention of investors seeking to decipher the behavior of company insiders. Headquartered in Austin, Texas, Natera, Inc. specializes in genetic testing and diagnostics, providing services in areas such as prenatal screening and cancer detection.

Investment Professional Insights

Natera, Inc. (NASDAQ: NTRA ) is going through a period where insider trading has come under heightened scrutiny, and the company's financial metrics and market performance provide investors with broader context. Despite internal sales, Natera has seen a significant uptick in market activity recently, 40.07% Total price returns over the past three months have been impressive 139.57% Performance over the past six months reflects strong investor confidence.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

InvestingPro data highlights the company's strong revenue growth, showing in the trailing twelve months to fourth quarter 2023 31.99% The increase in revenue shows that Natera's market share in the field of genetic testing continues to expand. But it's worth noting that the company is not yet profitable and has a negative price-to-earnings ratio. -24.25 and adjusted price-to-earnings ratio for the same period -25.77.

Two InvestingPro tips for Natera include the company's high returns over the last year and its strong returns over the past three months. These metrics suggest that despite not being profitable in the last twelve months, the company's shares have provided solid returns for investors who held shares during that period. Additionally, Natera's liquid assets exceed its short-term debt, which may provide some assurance about the company's financial stability.

For investors seeking a deeper understanding of Natera's performance and potential, InvestingPro provides a wealth of additional insights. Through a series of InvestingPro Tips, users can have a more comprehensive understanding of the company's financial status and market position.To get these insights and more, consider using the coupon code PRONEWS24 Annual or biennial Pro and Pro+ subscriptions receive an additional 10% discount.

This article was generated with the support of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *